Entellus Medical, Inc. (NASDAQ:ENTL) has received an average recommendation of “Hold” from the nine research firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $19.75.

Several research firms have recently issued reports on ENTL. Zacks Investment Research cut shares of Entellus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, October 31st. BidaskClub cut shares of Entellus Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Piper Jaffray Companies reiterated a “buy” rating and set a $21.00 price objective on shares of Entellus Medical in a research report on Tuesday, August 22nd. Finally, Canaccord Genuity reissued a “hold” rating and issued a $17.00 target price on shares of Entellus Medical in a report on Tuesday, October 17th.

In related news, VP Timothy B. Petrick sold 2,000 shares of the firm’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $20.01, for a total value of $40,020.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Brian E. Farley sold 40,000 shares of the firm’s stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $19.78, for a total transaction of $791,200.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 92,150 shares of company stock valued at $1,740,652. 7.70% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its stake in Entellus Medical by 29.4% during the second quarter. Bank of New York Mellon Corp now owns 40,783 shares of the medical technology company’s stock worth $675,000 after buying an additional 9,270 shares during the period. Nicholas Company Inc. boosted its stake in Entellus Medical by 1,052.3% during the second quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock worth $4,101,000 after buying an additional 226,190 shares during the period. William Blair Investment Management LLC boosted its stake in Entellus Medical by 10.5% during the second quarter. William Blair Investment Management LLC now owns 431,187 shares of the medical technology company’s stock worth $7,140,000 after buying an additional 40,853 shares during the period. Archon Capital Management LLC boosted its stake in Entellus Medical by 34.3% during the second quarter. Archon Capital Management LLC now owns 478,820 shares of the medical technology company’s stock worth $7,929,000 after buying an additional 122,171 shares during the period. Finally, Wasatch Advisors Inc. boosted its stake in Entellus Medical by 6.7% during the second quarter. Wasatch Advisors Inc. now owns 231,656 shares of the medical technology company’s stock worth $3,836,000 after buying an additional 14,462 shares during the period. 70.96% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/entellus-medical-inc-entl-given-consensus-recommendation-of-hold-by-brokerages/1721683.html.

Entellus Medical (NASDAQ ENTL) traded up $0.15 during trading on Thursday, hitting $16.33. 131,900 shares of the stock traded hands, compared to its average volume of 164,290. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32. Entellus Medical has a 52-week low of $11.47 and a 52-week high of $20.34.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.